MarketCap
Facebook
X
Telegram
Mirum Pharmaceuticals Financial Ratios 2025-2011 | MIRM
Brief overview of Mirum Pharmaceuticals's market valuation
Current figures are compared with the company's own five-year history for 2021–2025.
Key multiples at the end of the period are P/S 10.45x (median 10.38x), P/B 17.31x (median 5.63x). Valuation is 104% above five-year reference levels. The premium requires support from earnings and returns.
Returns on assets and capital are represented by ROE -7.4%, ROA -2.8%, ROCE -7%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
On PEG (6.72x), valuation is stretched relative to growth and requires strong execution.
A longer cycle, from 31.1 days to 70.6 days, indicates slower release of cash from operations.
Valuation takeaway
Mirum Pharmaceuticals combines weak profitability with valuation above its historical norm, leaving limited cushion.
Annual Financial Ratios Mirum Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-233.2 | -27.4 | -6.7 | -5.9 | -5.8 | -4.6 | -3.7 | - | - | - | - | - | - | - | - |
P/S |
10.4 | 7.2 | 5.9 | 10.4 | 25.3 | - | - | - | - | - | - | - | - | - | - |
EPS |
-0.5 | -1.9 | -4 | -4.0 | -2.8 | -4.1 | -4.6 | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
5.68 B | 2.64 B | 1.21 B | 983 M | 627 M | 400 M | 198 M | 62.3 M | - | - | - | - | - | - | - |
EBITDA per Share |
0.04 | -1.35 | -2.4 | -3.78 | -5.7 | -3.97 | -4.74 | - | - | - | - | - | - | - | - |
EV/EBITDA |
2694.0 | -41.2 | -12.3 | -7.7 | -3.5 | -3.2 | -3.3 | - | - | - | - | - | - | - | - |
PEG |
6.72 | 1.58 | - | - | - | -0.43 | 0.81 | - | - | - | - | - | - | - | - |
P/B |
17.3 | 10.7 | 4.4 | 5.6 | 4.0 | 2.7 | 1.5 | - | - | - | - | - | - | - | - |
P/CF |
97.6 | 233.8 | -15.4 | -6.7 | -3.6 | -5.3 | -4.9 | - | - | - | - | - | - | - | - |
ROE % |
-7.42 | -38.97 | -65.72 | -95.51 | -69.87 | -60.01 | -40.32 | - | - | - | - | - | - | - | - |
ROA % |
-2.77 | -13.11 | -25.27 | -38.44 | -28.50 | -42.87 | -35.82 | - | - | - | - | - | - | - | - |
ROCE % |
-7.03 | -38.83 | -43.90 | -92.38 | -144.26 | -46.90 | -40.96 | - | - | - | - | - | - | - | - |
Current Ratio |
1.6 | 1.5 | 1.6 | 1.7 | 1.7 | 12.8 | 9.1 | - | - | - | - | - | - | - | - |
DSO |
70.6 | 79.2 | 90.1 | 64.6 | 31.2 | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
70.6 | 79.2 | 90.0 | 64.6 | 31.1 | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
70.6 | 79.2 | 90.0 | 64.6 | 31.1 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Mirum Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.06 | -13.43 | 0.06 | -0.12 | -0.3 | - | -0.3 | -0.52 | -0.54 | - | -0.57 | -1.94 | -0.8 | - | -1.02 | -0.84 | -1.17 | - | -1.55 | -1.45 | -1.68 | - | -0.86 | -0.93 | -0.86 | - | -0.84 | -5.31 | -2.37 | - | -0.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.45 | -13.3 | 0.17 | 0.02 | -0.19 | - | -0.14 | -0.39 | -0.44 | - | -0.55 | -0.6 | -0.69 | - | -0.91 | -0.96 | -1.04 | - | -1.4 | -1.24 | -1.58 | - | -0.86 | -0.94 | -0.89 | - | -0.88 | -5.48 | -2.46 | - | -0.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
317.90 | -333.44 | -13.73 | -25.48 | -33.96 | -27.67 | -36.44 | -124.48 | -135.07 | -124.30 | -145.39 | -160.94 | -100.36 | -79.02 | -162.55 | -187.31 | -200.73 | -167.12 | -179.62 | -109.60 | -76.13 | -38.39 | -49.96 | -47.87 | -38.93 | -26.54 | -26.16 | -14.53 | -4.57 | - | 0.39 | 0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-95.56 | -91.25 | -4.70 | -8.79 | -11.86 | -9.74 | -13.36 | -27.92 | -33.23 | -29.35 | -39.15 | -48.69 | -52.03 | -42.99 | -60.72 | -50.92 | -73.65 | -60.49 | -69.42 | -59.04 | -50.17 | -27.43 | -37.71 | -38.02 | -32.43 | -23.58 | -23.71 | -13.45 | -4.06 | - | -0.13 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
81.52 | -333.13 | -13.04 | -24.51 | -33.84 | -27.33 | -36.68 | -62.09 | -70.74 | -59.46 | -78.88 | -97.94 | -97.11 | -77.88 | -153.81 | -173.46 | -180.62 | -150.56 | -163.18 | -100.96 | -74.70 | -39.13 | -51.31 | -49.45 | -40.49 | -27.68 | -27.31 | -10.77 | -4.74 | - | 0.38 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.0 | 1.4 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.7 | 1.2 | 1.7 | 1.7 | 1.9 | - | 1.6 | 1.7 | 1.3 | 1.6 | 2.5 | 3.5 | 3.5 | 3.5 | 3.5 | 9.0 | 9.0 | 9.0 | 9.0 | 21.2 | 21.2 | 21.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
72.1 | 68.6 | 73.4 | 72.4 | 71.2 | - | 65.1 | 67.6 | 81.0 | - | 79.5 | 73.0 | 70.2 | - | 39.7 | 20.5 | 39.4 | - | 3.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 73.4 | 72.4 | 71.2 | - | 65.1 | 67.6 | 81.0 | - | 79.5 | 73.0 | 70.2 | - | 39.7 | 20.5 | 39.4 | - | 3.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 73.4 | 72.4 | 71.2 | - | 65.1 | 67.6 | 81.0 | - | 79.5 | 73.0 | 70.2 | - | 39.7 | 20.5 | 39.4 | - | 3.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Mirum Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
